The Src Homology 2 Containing Inositol 5′ Phosphatases

Handbook of Cell Signaling, Second Edition

Volumn 2, Issue , 2009, Pages 1065-1083

  Antignano, Frann ^a   Ruschmann, Jens ^a   Hamilton, Melisa ^a   Ho, Victor ^a   Lam, Vivian ^a   Kuroda, Etsushi ^a   Sly, Laura M ^a   Krystal, Gerald ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951483658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00134-0     Document Type: Chapter

References (206)

1. G Krystal (2000) Lipid phosphatases in the immune system. Semin Immunol 12 397-403.
2. LM Sly, MJ Rauh, J Kalesnikoff, T Buchse and G Krystal (2003) SHIP, SHIP2 and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is upregulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 31 1170-1181.
3. CP Downes, NR Leslie, IH Batty and KJ van der (2007) Metabolic switching of PI3K-dependent lipid signals. Biochem Soc Trans 35 188-192.
4. A Salmeen and D Barford (2005) Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid Redox Signal 7 560-577.
5. Y Lu, Q Yu, JH Liu, J Zhang, H Wang, D Koul, JS McMurray, X Fang, WK Yung, KA Siminovitch and GB Mills (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278 40,057-40,066.
6. MJ Fry (2001) Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 3 304-312.
7. IG Campbell, SE Russell, DY Choong, KG Montgomery, ML Ciavarella, CS Hooi, BE Cristiano, RB Pearson and WA Phillips (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64 7678-7681.
8. BT Hennessy, DL Smith, PT Ram, Y Lu and GB Mills (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 988-1004.
9. LC Cantley and BG Neel (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96 4240-4245.
10. AE Frimberger, CI McAuliffe, KA Werme, RA Tuft, KE Fogarty, BO Benoit, MS Dooner and PJ Quesenberry (2001) The fleet feet of haematopoietic stem cells: rapid motility, interaction and proteopodia. Br J Haematol 112 644-654.
11. T Sasaoka, T Wada and H Tsuneki (2006) Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 112 799-809.
12. MV Astle, KA Horan, LM Ooms and CA Mitchell (2007) The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors? Biochem Soc Symp 74 161-181.
13. LR Rohrschneider, JF Fuller, I Wolf, Y Liu and DM Lucas (2000) Structure, function, and biology of SHIP proteins. Genes Dev 14 505-520.
14. M Kashiwada, P Lu and PB Rothman (2007) PIP3 pathway in regulatory T cells and autoimmunity. Immunol Res 39 194-224.
15. SJ Harris, RV Parry, J Westwick and SG Ward (2008) Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem 283 2465-2469.
16. G Gloire, C Erneux and J Piette (2007) The role of SHIP1 in T-lymphocyte life and death. Biochem Soc Trans 35 277-280.
17. Gratacap MP, Severin S, Chicanne G, Plantavid M, Payrastre B. Different roles of SHIP1 according to the cell context: The example of blood platelets. Adv Enzyme Regul 2008. epub ahead of print.
18. MC Sweeney, AS Wavreille, J Park, JP Butchar, S Tridandapani and D Pei (2005) Decoding protein–protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. Biochemistry 44 14,932-14,947.
19. AS Wavreille, M Garaud, Y Zhang and D Pei (2007) Defining SH2 domain and PTP specificity by screening combinatorial peptide libraries. Methods 42 207-219.
20. K Yogo, M Mizutamari, K Mishima, H Takenouchi, N Ishida-Kitagawa, T Sasaki and T Takeya (2006) Src homology 2 (SH2)-containing 5′-inositol phosphatase localizes to podosomes, and the SH2 domain is implicated in the attenuation of bone resorption in osteoclasts. Endocrinology 147 3307-3317.
21. X Pesesse, K Backers, C Moreau, J Zhang, D Blero, N Paternotte and C Erneux (2006) SHIP1/2 interaction with tyrosine phosphorylated peptides mimicking an immunoreceptor signalling motif. Adv Enzyme Regul 46 142-153.
22. D Wisniewski, A Strife, S Swendeman, H Erdjument-Bromage, S Geromanos, WM Kavanaugh, P Tempst and B Clarkson (1999) A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93 2707-2720.
23. M Song, MJ Kim, S Ha, JB Park, SH Ryu and PG Suh (2005) Inositol 5′-phosphatase, SHIP1 interacts with phospholipase C-γ1 and modulates EGF-induced PLC activity. Exp Mol Med 37 161-168.
24. M Ono, S Bolland, P Tempst and JV Ravetch (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc-γ RIIB. Nature 383 263-266.
25. SJ Geier, PA Algate, K Carlberg, D Flowers, C Friedman, B Trask and LR Rohrschneider (1997) The human SHIP gene is differentially expressed in cell lineages of the bone marrow and blood. Blood 89 1876-1885.
26. N Gupta, AM Scharenberg, DA Fruman, LC Cantley, JP Kinet and EO Long (1999) The SH2 domain-containing inositol 5′-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcγRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem 274 7489-7494.
27. DM Lucas and LR Rohrschneider (1999) A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. Blood 93 1922-1933.
28. I Dybedal, D Bryder, A Fossum, LS Rusten and SE Jacobsen (2001) Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 98 1782-1791.
29. JE Damen, L Liu, MD Ware, M Ermolaeva, PW Majerus and G Krystal (1998) Multiple forms of SHIP are generated by C-terminal truncation. Blood 92 1199-1205.
30. S Horn, J Meyer, J Heukeshoven, B Fehse, C Schulze, S Li, J Frey, S Poll, C Stocking and M Jucker (2001) The inositol 5-phosphatase SHIP is expressed as 145- and 135-kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro. Leukemia 15 112-120.
31. LM Sly, MJ Rauh, J Kalesnikoff, CH Song and G Krystal (2004) LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21 227-239.
32. J Cuschieri, E Bulger, R Grinsell, I Garcia and RV Maier (2007) Insulin regulates macrophage activation through Activin A1. Shock 29 285-290.
33. M Sattler, R Salgia, G Shrikhande, S Verma, JL Choi, LR Rohrschneider and JD Griffin (1997) The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene 15 2379-2384.
34. WM Kavanaugh, DA Pot, SM Chin, M Deuter-Reinhard, AB Jefferson, FA Norris, FR Masiarz, LS Cousens, PW Majerus and LT Williams (1996) Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2. Curr Biol 6 438-445.
35. Z Tu, JM Ninos, Z Ma, J-W Wang, MP Lemos, C Desponts, T Ghansah, JM Howson and WG Kerr (2001) Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein. Blood 98 2028-2038.
36. LR Rohrschneider, JM Custodio, TA Anderson, CP Miller and H Gu (2005) The intron 5/6 promoter region of the ship1 gene regulates expression in stem/progenitor cells of the mouse embryo. Dev Biol 283 503-521.
37. Q Liu, F Shalaby, J Jones, D Bouchard and DJ Dumont (1998) The SH2-containing inositol polyphosphate 5-phosphatase, ship, is expressed during hematopoiesis and spermatogenesis. Blood 91 2753-2759.
38. A Zippo, A De Robertis, M Bardelli, F Galvagni and S Oliviero (2004) Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103 4536-4544.
39. I Wolf, DM Lucas, PA Algate and LR Rohrschneider (2000) Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIPδ. Genomics 69 104-112.
40. J Kalesnikoff, LM Sly, MR Hughes, T Buchse, MJ Rauh, L-P Cao, V Lam, A Mui, M Huber, G Krystal, et al. (2003) The role of SHIP in cytokine-induced signaling. SG Amara, E Bamberg, MP Blaustein (Eds) Reviews of physiology, biochemistry and pharmacology Heidelberg, Germany: Springer-Verlag 87-103.
41. J Siegel, Y Li and P Whyte (1999) SHIP-mediated inhibition of K562 erythroid differentiation requires an intact catalytic domain and Shc binding site. Oncogene 18 7135-7148.
42. A Brauweiler, I Tamir, S Marschner, CD Helgason and JC Cambier (2001) Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. J Immunol 167 204-211.
43. DL Maresco, JM Osborne, D Cooney, KM Coggeshall and CL Anderson (1999) The SH2-containing 5′-inositol phosphatase (SHIP) is tyrosine phosphorylated after Fcγ receptor clustering in monocytes. J Immunol 162 6458-6465.
44. S Giuriato, B Payrastre, AL Drayer, M Plantavid, R Woscholski, P Parker, C Erneux and H Chap (1997) Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets. J Biol Chem 272 26857-26863.
45. D Cox, BM Dale, M Kashiwada, CD Helgason and S Greenberg (2001) A regulatory role for Src homology 2 domain-containing inositol 5′- phosphatase (SHIP) in phagocytosis mediated by Fcγ receptors and complement receptor 3 (αMβ2; CD11b/CD18). J Exp Med 193 61-71.
46. R Trotta, R Parihar, J Yu, B Becknell, J Allard, J Wen, W Ding, H Mao, S Tridandapani, WE Carson and MA Caligiuri (2005) Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood 105 3011-3018.
47. H Valderrama-Carvajal, E Cocolakis, A Lacerte, EH Lee, G Krystal, S Ali and JJ Lebrun (2002) Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol 4 963-969.
48. A Mandl, D Sarkes, V Carricaburu, V Jung and L Rameh (2007) Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN. Mol Cell Biol 27 8098-8112.
49. R Martino, MD Caballero, C Canals, P Simón, C Solano, A Urbano-Ispízua, J Bargay, C Rayón, A Léon, J Sarrá, J Odriozola, JG Conde, J Sierra and JS Miguel (2001) Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 115 653-659.
50. X Jiang, M Stuible, Y Chalandon, A Li, WY Chan, W Eisterer, G Krystal, A Eaves and C Eaves (2003) Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 102 2976-2984.
51. JM Vanderwinden, D Wang, N Paternotte, S Mignon, K Isozaki and C Erneux (2006) Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT. Cell Signal 18 661-669.
52. SV Mikhalap, LM Shlapatska, AG Berdova, CL Law, EA Clark and SP Sidorenko (1999) CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 162 5719-5727.
53. E Muraille, X Pesesse, C Kuntz and C Erneux (1999) Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells. Biochem J 342 697-705.
54. C Bruyns, X Pesesse, C Moreau, D Blero and C Erneux (1999) The two SH2-domain-containing inositol 5-phosphatases SHIP1 and SHIP2 are coexpressed in human T lymphocytes. Biol Chem 380 969-974.
55. JH Raaijmakers, L Deneubourg, H Rehmann, J de Koning, Z Zhang, S Krugmann, C Erneux and JL Bos (2007) The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase SHIP2 in a SAM domain-dependent manner. Cell Signal 19 1249-1257.
56. G Zhuang, S Hunter, Y Hwang and J Chen (2007) Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation. J Biol Chem 282 2683-2694.
57. X Pesesse, S Deleu, F De Smedt, L Drayer and C Erneux (1997) Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 239 697-700.
58. JE Damen, MD Ware, J Kalesnikoff, MR Hughes and G Krystal (2001) SHIP’s C-terminus is essential for its hydrolysis of PIP3 and inhibition of mast cell degranulation. Blood 97 1343-1351.
59. MJ Aman, SF Walk, ME March, HP Su, DJ Carver and KS Ravichandran (2000) Essential role for the C-terminal noncatalytic region of SHIP in FcγRIIB1-mediated inhibitory signaling. Mol Cell Biol 20 3576-3589.
60. H Hori, T Sasaoka, H Ishihara, T Wada, S Murakami, M Ishiki and M Kobayashi (2002) Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 51 2387-2394.
61. CD Helgason, JE Damen, P Rosten, R Grewal, P Sorensen, SM Chappel, A Borowski, F Jirik, G Krystal and RK Humphries (1998) Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12 1610-1620.
62. Q Liu, AJ Oliveira-Dos-Santos, S Mariathasan, D Bouchard, J Jones, R Sarao, I Kozieradzki, PS Ohashi, JM Penninger and DJ Dumont (1998) The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J Exp Med 188 1333-1342.
63. SY Oh, T Zheng, ML Bailey, DL Barber, JT Schroeder, YK Kim and Z Zhu (2007) Src homology 2 domain-containing inositol 5-phosphatase 1 deficiency leads to a spontaneous allergic inflammation in the murine lung. J Allergy Clin Immunol 119 123-131.
64. CH Kim, G Hangoc, S Cooper, CD Helgason, S Yew, RK Humphries, G Krystal and HE Broxmeyer (1999) Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest 104 1751-1759.
65. JM Mason, A Halupa, D Hyam, NN Iscove, DJ Dumont and DL Barber (2002) Blood 100 519a. (Abstract)
66. K Nakamura, T Kouro, PW Kincade, A Malykhin, K Maeda and KM Coggeshall (2004) Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow. J Exp Med 199 243-254.
67. M Kashiwada, G Cattoretti, L McKeag, T Rouse, BM Showalter, U Al Alem, M Niki, PP Pandolfi, EH Field and PB Rothman (2006) Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5′-phosphatase are required for regulation of CD4+CD25+ T cell development. J Immunol 176 3958-3965.
68. T Tarasenko, HK Kole, AW Chi, MM Mentink-Kane, TA Wynn and S Bolland (2007) T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci USA 104 11,382-11,387.
69. S Takeshita, N Namba, JJ Zhao, Y Jiang, HK Genant, MJ Silva, MD Brodt, CD Helgason, J Kalesnikoff, MJ Rauh, RK Humphries, G Krystal, SL Teitelbaum and FP Ross (2002) SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8 943-949.
70. JW Wang, JM Howson, T Ghansah, C Desponts, JM Ninos, SL May, KH Nguyen, N Toyama-Sorimachi and WG Kerr (2002) Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295 2094-2097.
71. T Ghansah, KH Paraiso, S Highfill, C Desponts, S May, JK McIntosh, JW Wang, J Ninos, J Brayer, F Cheng, E Sotomayor and WG Kerr (2004) Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol 173 7324-7330.
72. MJ Rauh, V Ho, C Pereira, A Sham, LM Sly, V Lam, L Huxham, AI Minchinton, A Mui and G Krystal (2005) SHIP represses the generation of alternatively activated macrophages. Immunity 23 361-374.
73. JA Fox, K Ung, SG Tanlimco and FR Jirik (2002) Disruption of a single Pten allele augments the chemotactic response of B lymphocytes to stromal cell-derived factor-1. J Immunol 169 49-54.
74. S Clement, U Krause, F Desmedt, JF Tanti, J Behrends, X Pesesse, T Sasaki, J Penninger, M Doherty, W Malaisse, JE Dumont, Y Marchand-Brustel, C Erneux, L Hue and S Schurmans (2001) The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409 92-97.
75. S Clement, U Krause, F Desmedt, JF Tanti, J Behrends, X Pesesse, T Sasaki, J Penninger, M Doherty, W Malaisse, JE Dumont, Y Marchand-Brustel, C Erneux, L Hue and S Schurmans (2004) corrigendum: the lipid phosphatase SHIP2 controls insulin sensitivity. Nature 431 878.
76. MW Sleeman, KE Wortley, KM Lai, LC Gowen, J Kintner, WO Kline, K Garcia, TN Stitt, GD Yancopoulos, SJ Wiegand and DJ Glass (2005) Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11 199-205.
77. CP Baran, S Tridandapani, CD Helgason, RK Humphries, G Krystal and CB Marsh (2003) The inositol 5′-phosphatase SHIP-1 and the Src kinase lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem 278 38,628-38,636.
78. MJ Maxwell, Y Yuan, KE Anderson, ML Hibbs, HH Salem and SP Jackson (2004) SHIP1 and lyn kinase negatively regulate integrin αIIbβ3 signalling in platelets. J Biol Chem 279 32,196-32,204.
79. JE Damen, L Liu, P Rosten, RK Humphries, AB Jefferson, PW Majerus and G Krystal (1996) The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc Natl Acad Sci USA 93 1689-1693.
80. H Phee, A Jacob and KM Coggeshall (2000) Enzymatic activity of the Src homology 2 domain-containing inositol phosphatase is regulated by a plasma membrane location. J Biol Chem 275 19,090-19,097.
81. H Phee, W Rodgers and KM Coggeshall (2001) Visualization of negative signaling in B cells by quantitative confocal microscopy. Mol Cell Biol 21 8615-8625.
82. L Liu, JE Damen, MD Ware and G Krystal (1997) Interleukin-3 induces the association of the inositol 5-phosphatase SHIP with SHP2. J Biol Chem 272 10,998-11,001.
83. S Marchetto, E Fournier, N Beslu, T Aurran-Schleinitz, P Dubreuil, JP Borg, D Birnbaum and O Rosnet (1999) SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 13 1374-1382.
84. R Galandrini, I Tassi, S Morrone, L Lanfrancone, P Pelicci, M Piccoli, L Frati and A Santoni (2001) The adaptor protein shc is involved in the negative regulation of NK cell-mediated cytotoxicity. Eur J Immunol 31 2016-2025.
85. S Tridandapani, Y Wang, CB Marsh and CL Anderson (2002) Src homology 2 domain-containing inositol polyphosphate phosphatase regulates NF-κB-mediated gene transcription by phagocytic FcγRs in human myeloid cells. J Immunol 169 4370-4378.
86. L Velazquez, GD Gish, GP van Der, L Taylor, J Shulman and T Pawson (2000) The shc adaptor protein forms interdependent phosphotyrosine-mediated protein complexes in mast cells stimulated with interleukin 3. Blood 96 132-138.
87. H Bone and MJ Welham (2000) Shc associates with the IL-3 receptor β subunit, SHIP and Gab2 following IL-3 stimulation. Contribution of Shc PTB and SH2 domains. Cell Signal 12 183-194.
88. S Tridandapani, M Pradhan, JR LaDine, S Garber, CL Anderson and KM Coggeshall (1999) Protein interactions of Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP): association with Shc displaces SHIP from FcγRIIb in B cells. J Immunol 162 1408-1414.
89. R Galandrini, I Tassi, G Mattia, L Lenti, M Piccoli, L Frati and A Santoni (2002) SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood 100 4581-4589.
90. HS Ramshaw, MA Guthridge, FC Stomski, EF Barry, L Ooms, CA Mitchell, CG Begley and AF Lopez (2007) The Shc-binding site of the betac subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood 110 3582-3590.
91. CJ Ong, A Ming-Lum, M Nodwell, A Ghanipour, L Yang, DE Williams, J Kim, D Loutfig, Q Pooran, J Ruschmann, L-P Cao, K-W Ma, SW Chung, V Duronio, RJ Andersen, G Krystal and AL-F Mui (2007) Small molecule agonists of SHIP inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110 1942-1949.
92. JM Dyson, CJ O’Malley, J Becanovic, AD Munday, MC Berndt, ID Coghill, HH Nandurkar, LM Ooms and CA Mitchell (2001) The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J Cell Biol 155 1065-1079.
93. R Lesourne, WH Fridman and M Daeron (2005) Dynamic interactions of Fcγ receptor IIB with filamin-bound SHIP1 amplify filamentous actin-dependent negative regulation of Fcε receptor I signaling. J Immunol 174 1365-1373.
94. Y Feng, SR Wente and PW Majerus (2001) Overexpression of the inositol phosphatase SopB in human 293 cells stimulates cellular chloride influx and inhibits nuclear mRNA export. Proc Natl Acad Sci USA 98 875-879.
95. HR Luo, YE Huang, JC Chen, A Saiardi, M Iijima, K Ye, Y Huang, E Nagata, P Devreotes and SH Snyder (2003) Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell 114 559-572.
96. A Saiardi, R Bhandari, AC Resnick, AM Snowman and SH Snyder (2004) Phosphorylation of proteins by inositol pyrophosphates. Science 306 2101-2105.
97. M Bennett, SM Onnebo, C Azevedo and A Saiardi (2006) Inositol pyrophosphates: metabolism and signaling. Cell Mol Life Sci 63 552-564.
98. MP Scheid, M Huber, JE Damen, M Hughes, V Kang, P Neilsen, GD Prestwich, G Krystal and V Duronio (2002) Phosphatidylinositol(3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation: Phosphatidylinositol(3,4)P2 is required for PKB phosphorylation at Ser473. Studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 277 9027-9035.
99. AJ Marshall, AK Krahn, K Ma, V Duronio and S Hou (2002) TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor. Mol Cell Biol 22 5479-5491.
100. AK Krahn, K Ma, S Hou, V Duronio and AJ Marshall (2004) Two distinct waves of membrane-proximal B cell antigen receptor signaling differentially regulated by Src homology 2-containing inositol polyphosphate 5-phosphatase. J Immunol 172 331-339.
101. A Allam and AJ Marshall (2005) Role of the adaptor proteins Bam32, TAPP1 and TAPP2 in lymphocyte activation. Immunol Letts 97 7-17.
102. M Krause, JD Leslie, M Stewart, EM Lafuente, F Valderrama, R Jagannathan, GA Strasser, DA Rubinson, H Liu, M Way, MB Yaffe, VA Boussiotis and FB Gertler (2004) Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell 7 571-583.
103. M Huber, CD Helgason, MP Scheid, V Duronio, RK Humphries and G Krystal (1998) Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J 17 7311-7319.
104. M Huber, CD Helgason, JE Damen, MP Scheid, V Duronio, V Lam, RK Humphries and G Krystal (1999) The role of SHIP in FcεRI-induced signalling. M Daeron, E Vivier (Eds) Current topics in microbiology and immunology Berlin: Springer 19-41.
105. G Koncz, GK Toth, G Bokonyi, G Keri, I Pecht, D Medgyesi, J Gergely and G Sarmay (2001) Co-clustering of Fcγ and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein. Eur J Biochem 268 3898-3906.
106. SP Forestell, E Bohnlein and RJ Rigg (1995) Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Ther 2 723-730.
107. JD Robson, D Davidson and A Veillette (2004) Inhibition of the Jun N-terminal protein kinase pathway by SHIP-1, a lipid phosphatase that interacts with the adaptor molecule Dok-3. Mol Cell Biol 24 2332-2343.
108. KM Coggeshall (1998) Inhibitory signaling by B cell Fcγ RIIb. Curr Opin Immunol 10 306-312.
109. H Ishihara, T Sasaoka, H Hori, T Wada, H Hirai, T Haruta, WJ Langlois and M Kobayashi (1999) Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and its role in the regulation of insulin signaling. Biochem Biophys Res Commun 260 265-272.
110. MG Tomlinson, VL Heath, CW Turck, SP Watson and A Weiss (2004) SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase. J Biol Chem 279 55,089-55,096.
111. X Pesesse, C Moreau, AL Drayer, R Woscholski, P Parker and C Erneux (1998) The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity. FEBS Letts 437 301-303.
112. T Maehama and JE Dixon (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 13,375-13,378.
113. N Paternotte, J Zhang, I Vandenbroere, K Backers, D Blero, N Kioka, JM Vanderwinden, I Pirson and C Erneux (2005) SHIP2 interaction with the cytoskeletal protein Vinexin. FEBS J 272 6052-6066.
114. F Vandeput, K Backers, V Villeret, X Pesesse and C Erneux (2006) The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity. Cell Signal 18 2193-2199.
115. QL Zhou, JG Park, ZY Jiang, JJ Holik, P Mitra, S Semiz, A Guilherme, AM Powelka, X Tang, J Virbasius and MP Czech (2004) Analysis of insulin signalling by RNAi-based gene silencing. Biochem Soc Trans 32 817-821.
116. X Tang, AM Powelka, NA Soriano, MP Czech and A Guilherme (2005) PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J Biol Chem 280 22,523-22,529.
117. OH Yilmaz, R Valdez, BK Theisen, W Guo, DO Ferguson, H Wu and SJ Morrison (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 475-482.
118. CD Helgason, J Antonchuk, C Bodner and RK Humphries (2003) Homeostatis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice. Blood 102 3541-3547.
119. C Desponts, AL Hazen, KH Paraiso and WG Kerr (2006) SHIP deficiency enhances HSC proliferation and survival but compromises homing and repopulation. Blood 107 4338-4345.
120. C Desponts, JM Ninos and WG Kerr (2006) s-SHIP associates with receptor complexes essential for pluripotent stem cell growth and survival. Stem Cells Dev 15 641-646.
121. MJ Rauh, J Kalesnikoff, M Hughes, L Sly, V Lam and G Krystal (2003) The role of Src homology 2-containing-inositol 5′-phosphatases (SHIP) in mast cells and macrophages. Biochem Soc Trans 31 286-291.
122. M Buitenhuis, LP Verhagen, HW van Deutekom, A Castor, S Verploegen, L Koenderman, SE Jacobsen and PJ Coffer (2008) Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 111 112-121.
123. JM Luo, H Yoshida, S Komura, N Ohishi, L Pan, K Shigeno, I Hanamura, K Miura, S Iida, R Ueda, T Naoe, Y Akao, R Ohno and K Ohnishi (2003) Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17 1-8.
124. JM Luo, ZL Liu, HL Hao, FX Wang, ZR Dong and O Ryuzo (2004) Mutation analysis of SHIP gene in acute leukemia. Zhonghua Xue Ye Xue Za Zhi 25 385-388.
125. DC Gilby, AC Goodeve, PR Winship, PJ Valk, R Delwel and JT Reilly (2007) Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia 21 2390-2393.
126. Y Okayama and T Kawakami (2006) Development, migration, and survival of mast cells. Immunol Res 34 97-115.
127. M Huber, CD Helgason, JE Damen, M Scheid, V Duronio, L Liu, MD Ware, RK Humphries and G Krystal (1999) The role of SHIP in growth factor induced signalling. Prog Biophys Mol Biol 71 423-434.
128. J Kalesnikoff, N Baur, M Leitges, MR Hughes, JE Damen, M Huber and G Krystal (2002) SHIP negatively regulates IgE+ antigen-induced IL-6 production in mast cells by inhibiting NFκB activity. J Immunol 168 4737-4746.
129. M Leitges, K Gimborn, W Elis, J Kalesnikoff, MR Hughes, G Krystal and M Huber (2002) Protein kinase C-d is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol 22 3970-3980.
130. M Huber, JE Damen, M Ware, M Hughes, CD Helgason, RK Humphries and G Krystal (2000) Regulation of mast cell degranulation by SHIP. G Marone, LM Lichtenstein, SJ Galli (Eds) Mast cells and Basophils in physiology, pathology and host defense New York: Academic Press pp. 11, 169–82
131. J Kalesnikoff, V Lam and G Krystal (2002) SHIP represses mast cell activation and reveals that IgE alone triggers signalling pathways which enhance normal mast cell survival. Mol Immunol 38 1201-1206.
132. K Gimborn, E Lessmann, S Kuppig, G Krystal and M Huber (2005) SHIP down-regulates FCεR1-induced degranulation at supraoptimal IgE or antigen levels. J Immunol 174 507-516.
133. BF Gibbs, A Rathling, D Zillikens, M Huber and H Haas (2006) Initial Fcε RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol 118 1060-1067.
134. V Lam, J Kalesnikoff, CWK Lee, V Hernandez-Hansen, BS Wilson, JM Oliver and G Krystal (2003) IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE+antigen but distinct from those used by Steel factor. Blood 102 1405-1413.
135. D MacGlashan Jr and N Vilarino (2006) Nonspecific desensitization, functional memory, and the characteristics of SHIP phosphorylation following IgE-mediated stimulation of human basophils. J Immunol 177 1040-1051.
136. O Malbec, C Schmitt, P Bruhns, G Krystal, WH Fridman and M Daëron (2001) The Src homology 2 domain-containing Inositol 5-phosphatase 1 mediates cell cycle arrest by FcγRIIB. J Biol Chem 276 30,381-30,391.
137. SM MacDonald and BM Vonakis (2001) Association of the Src homology 2 domain-containing inositol 5′ phosphatase (SHIP) to releasability in human basophils. Mol Immunol 38 1323-1327.
138. DW MacGlashan Jr (2007) Relationship between spleen tyrosine kinase and phosphatidylinositol 5′ phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 119 626-633.
139. LP Ganesan, T Joshi, H Fang, VK Kutala, J Roda, R Trotta, A Lehman, P Kuppusamy, JC Byrd, WE Carson, MA Caligiuri and S Tridandapani (2006) FcγR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood 108 718-725.
140. V Vedham, H Phee and KM Coggeshall (2005) Vav activation and function as a rac guanine nucleotide exchange factor in macrophage colony-stimulating factor-induced macrophage chemotaxis. Mol Cell Biol 25 4211-4220.
141. KA Horan, K Watanabe, AM Kong, CG Bailey, JE Rasko, T Sasaki and CA Mitchell (2007) Regulation of FcγR-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3 mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup. Blood 110 4480-4491.
142. LA Kamen, J Levinsohn and JA Swanson (2007) Differential association of phosphatidylinositol 3-kinase, SHIP-1, and PTEN with forming phagosomes. Mol Biol Cell 18 2463-2472.
143. C Canetti, CH Serezani, RG Atrasz, ES White, DM Aronoff and M Peters-Golden (2007) Activation of phosphatase and tensin homolog on chromosome 10 mediates the inhibition of FcγR phagocytosis by prostaglandin E2 in alveolar macrophages. J Immunol 179 8350-8356.
144. J Ai, A Maturu, W Johnson, Y Wang, CB Marsh and S Tridandapani (2006) The inositol phosphatase SHIP-2 down-regulates FcγR-mediated phagocytosis in murine macrophages independently of SHIP-1. Blood 107 813-820.
145. Y Wang, RJ Keogh, MG Hunter, CA Mitchell, RS Frey, K Javaid, AB Malik, S Schurmans, S Tridandapani and CB Marsh (2004) SHIP2 is recruited to the cell membrane upon macrophage colony-stimulating factor (M-CSF) stimulation and regulates M-CSF-induced signaling. J Immunol 173 6820-6830.
146. MA West and W Heagy (2002) Endotoxin tolerance: a review. Crit Care Med 30 S64-S73.
147. H Fan and JA Cook (2004) Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10 71-84.
148. MJ Diaz-Guerra, A Castrillo, P Martin-Sanz and L Bosca (1999) Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol 162 6184-6190.
149. H Fang, RA Pengal, X Cao, LP Ganesan, MD Wewers, CB Marsh and S Tridandapani (2004) Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP. J Immunol 173 360-366.
150. TY Zhang and RA Daynes (2007) Macrophages from 11β-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-β-mediated up-regulation of SHIP1 expression. J Immunol 179 6325-6335.
151. K Saegusa, S Yotsumoto, S Kato and Y Aramaki (2007) Phosphatidylinositol 3-kinase-mediated regulation of IL-10 and IL-12 production in macrophages stimulated with CpG oligodeoxynucleotide. Mol Immunol 44 1323-1330.
152. M Martin, RE Schifferle, N Cuesta, SN Vogel, J Katz and SM Michalek (2003) Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 171 717-725.
153. CD Mills (2001) Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 21 399-425.
154. P Sinha, VK Clements, S Miller and S Ostrand-Rosenberg (2005) Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 54 1137-1142.
155. A Mantovani, S Sozzani, M Locati, P Allavena and A Sica (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 549-555.
156. S Gordon (2003) Alternative activation of macrophages. Nat Rev Immunol 3 23-35.
157. CE Lewis and JW Pollard (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66 605-612.
158. P Blanco, AK Palucka, V Pascual and J Banchereau (2008) Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19 41-52.
159. L Neill, AH Tien, J Rey-Ladino and CD Helgason (2007) SHIP-deficient mice provide insights into the regulation of dendritic cell development and function. Exp Hematol 35 627-639.
160. D Strassheim, JY Kim, JS Park, S Mitra and E Abraham (2005) Involvement of SHIP in TLR2-induced neutrophil activation and acute lung injury. J Immunol 174 8064-8071.
161. MG Hunter, A Jacob, LC O’Donnell, A Agler, LJ Druhan, KM Coggeshall and BR Avalos (2004) Loss of SHIP and CIS recruitment to the granulocyte colony–stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia. J Immunol 173 5036-5045.
162. S Gardai, BB Whitlock, C Helgason, D Ambruso, V Fadok, D Bratton and PM Henson (2002) Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem 277 5236-5246.
163. M Vaillancourt, S Levasseur, ML Tremblay, L Marois, E Rollet-Labelle and PH Naccache (2006) The Src homology 2-containing inositol 5-phosphatase 1 (SHIP1) is involved in CD32a signaling in human neutrophils. Cell Signal 18 2022-2032.
164. T Sasaki, J Sasaki, K Watanabe and A Suzuki (2007) Non-invasive visualization of the lipid product of class I PI3K in transgenic mouse models. Biochem Soc Trans 35 215-218.
165. M Nishio, K Watanabe, J Sasaki, C Taya, S Takasuga, R Iizuka, T Balla, M Yamazaki, H Watanabe, R Itoh, S Kuroda, Y Horie, I Forster, TW Mak, H Yonekawa, JM Penninger, Y Kanaho, A Suzuki and T Sasaki (2007) Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol 9 36-44.
166. N Kim, A Saudemont, L Webb, M Camps, T Ruckle, E Hirsch, M Turner and F Colucci (2007) The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110 3202-3208.
167. R Parihar III, R Trotta, JM Roda, AK Ferketich, S Tridandapani, MA Caligiuri and WE Carson (2005) Src homology 2-containing inositol 5′-phosphatase 1 negatively regulates IFN-g production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Res 65 9099-9107.
168. JA Wahle, KH Paraiso, RD Kendig, HR Lawrence, L Chen, J Wu and WG Kerr (2007) Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J Immunol 179 8009-8015.
169. S Giuriato, X Pesesse, S Bodin, T Sasaki, C Viala, E Marion, J Penninger, S Schurmans, C Erneux and B Payrastre (2003) SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem J 376 199-207.
170. J-M Pasquet, L Quek, C Stevens, R Bobe, M Huber, V Duronio, G Krystal and SP Watson (2000) Phosphatidylinositol 3,4,5-trisphosphate regulates Ca2+ entry via Btk in platelets and megakaryocytes without increasing phospholipase C activity. EMBO J 19 2793-2802.
171. S Severin, MP Gratacap, N Lenain, L Alvarez, E Hollande, JM Penninger, C Gachet, M Plantavid and B Payrastre (2007) Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. J Clin Invest 117 944-952.
172. I Isnardi, P Bruhns, G Bismuth, WH Fridman and M Daeron (2006) The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB and is mandatory for negative regulation of B cell activation. Immunol Letts 104 156-165.
173. A Brauweiler, I Tamir, J Dal Porto, RJ Benschop, CD Helgason, RK Humphries, JH Freed and JC Cambier (2000) Differential regulation of B cell development, activation, and death by the Src homology 2 domain-containing 5′ inositol phosphatase (SHIP). J Exp Med 191 1545-1554.
174. A Brauweiler, K Merrell, SB Gauld and JC Cambier (2007) Cutting Edge: Acute and chronic exposure of immature B cells to antigen leads to impaired homing and SHIP1-dependent reduction in stromal cell-derived factor-1 responsiveness. J Immunol 178 3353-3357.
175. I Tamir, JC Stolpa, CD Helgason, K Nakamura, P Bruhns, M Daeron and JC Cambier (2000) The RasGAP-binding protein-p62dok is a mediator of inhibitory FcγRIIB signals in B cells. Immunity 12 347-358.
176. KS Campbell (2007) Important port for SHIP-1 at Dok-3. Blood 110 3-4.
177. CM Wain, J Westwick and SG Ward (2005) Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes. Cell Signal 17 1194-1202.
178. MA Osborne, G Zenner, M Lubinus, X Zhang, Z Songyang, LC Cantley, P Majerus, P Burn and JP Kochan (1996) The inositol 5′-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation. J Biol Chem 271 29,271-29,278.
179. S Dong, B Corre, E Foulon, E Dufour, A Veillette, O Acuto and F Michel (2006) T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2. J Exp Med 203 2509-2518.
180. LJ Berg, LD Finkelstein, JA Lucas and PL Schwartzberg (2005) Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23 549-600.
181. WA Jensen, S Marschner, VL Ott and JC Cambier (2001) FcγRIIB-mediated inhibition of T-cell receptor signal transduction involves the phosphorylation of SH2-containing inositol 5-phosphatase (SHIP), dephosphorylation of the linker of activated T-cells (LAT) and inhibition of calcium mobilization. Biochem Soc Trans 29 840-846.
182. E Astoul, C Edmunds, DA Cantrell and SG Ward (2001) PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol 22 490-496.
183. MC Seminario, P Precht, SC Bunnell, SE Warren, CM Morris, D Taub and RL Wange (2004) PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt. Eur J Immunol 34 3165-3175.
184. X Shan, MJ Czar, SC Bunnell, P Liu, Y Liu, PL Schwartzberg and RL Wange (2000) Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 20 6945-6957.
185. G Gloire, E Charlier, S Rahmouni, C Volanti, A Chariot, C Erneux and J Piette (2006) Restoration of SHIP-1 activity in human leukemic cells modifies NF-κB activation pathway and cellular survival upon oxidative stress. Oncogene 25 5485-5494.
186. Y Imai and S Kohsaka (2002) Intracellular signaling in M-CSF-induced microglia activation: Role of Iba1. Glia 40 164-174.
187. MP Wymann, S Sozzani, F Altruda, A Mantovani and E Hirsch (2000) Lipids on the move: phosphoinositide 3-kinases in leukocyte function. Immunol Today 21 260-264.
188. LH Wang (2004) Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 71 361-367.
189. L Larue and A Bellacosa (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24 7443-7454.
190. A Koch, A Mancini, O El Bounkari and T Tamura (2005) The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24 3436-3447.
191. NK Prasad and SJ Decker (2005) SH2-containing 5′-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 280 13,129-13,136.
192. R DeKroon, JB Robinette, AB Hjelmeland, E Wiggins, M Blackwell, M Mihovilovic, M Fujii, J York, J Hart, C Kontos, J Rich and WJ Strittmatter (2006) APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. Circ Res 99 829-836.
193. E Marion, PJ Kaisaki, V Pouillon, C Gueydan, JC Levy, A Bodson, G Krzentowski, JC Daubresse, J Mockel, J Behrends, G Servais, C Szpirer, V Kruys, D Gauguier and S Schurmans (2002) The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 51 2012-2017.
194. LP van der Heide, GM Ramakers and MP Smidt (2006) Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 79 205-221.
195. K Aoki, T Nakamura, T Inoue, T Meyer and M Matsuda (2007) An essential role for the SHIP2-dependent negative feedback loop in neuritogenesis of nerve growth factor-stimulated PC12 cells. J Cell Biol 177 817-827.
196. L Baki, RL Neve, Z Shao, J Shioi, A Georgakopoulos and NK Robakis (2008) Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J Neurosci 28 483-490.
197. KY Lee, SH Koh, MY Noh, SH Kim and YJ Lee (2008) Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity. Toxicology 243 43-50.
198. H Zhang, R Liu, R Wang, S Hong, H Xu and YW Zhang (2007) Presenilins regulate the cellular level of the tumor suppressor PTEN. Neurobiol Aging 29 653-660.
199. T Crabbe, MJ Welham and SG Ward (2007) The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci 32 450-456.
200. C Ferrandi, V Ardissone, P Ferro, T Ruckle, P Zaratin, E Ammannati, E Hauben, C Rommel and R Cirillo (2007) Phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther 322 923-930.
201. UA Maus, M Backi, C Winter, M Srivastava, MK Schwarz, T Ruckle, JC Paton, D Briles, M Mack, T Welte, R Maus, RM Bohle, W Seeger, C Rommel, E Hirsch, J Lohmeyer and KT Preissner (2007) Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infection. Am J Respir Crit Care Med 175 958-966.
202. L Yang, DE Williams, A Mui, C Ong, G Krystal, R van Soest and RJ Andersen (2005) Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP. Organic Letts 7 1073-1076.
203. M Muthukuru and CW Cutler (2006) Upregulation of immunoregulatory Src homology 2 molecule containing inositol phosphatase and mononuclear cell hyporesponsiveness in oral mucosa during chronic periodontitis. Infect Immun 74 1431-1435.
204. P Zhou, H Kitaura, SL Teitelbaum, G Krystal, FP Ross and S Takeshita (2006) SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alternations in D-type cyclins and p27. J Immunol 177 8777-8784.
205. A Metzner, MA Horstmann, B Fehse, G Ortmeyer, CM Niemeyer, C Stocking, GW Mayr and M Jucker (2007) Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Gene Ther 14 699-703.
206. MV Astle, G Seaton, EM Davies, CG Fedele, P Rahman, L Arsala and CA Mitchell (2006) Regulation of phosphoinositide signaling by the inositol polyphosphate 5-phosphatases. IUBMB Life 58 451-456.